Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes

Ashish Ashish; Kusum Kusum; Sangeeta Rai; Radha Chaube; Shivani Mishra; Royana Singh

doi:doi:10.11648/j.reports.20210102.11

| Peer-Reviewed

Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes

Ashish Ashish, Kusum Kusum, Sangeeta Rai, Radha Chaube, Shivani Mishra, Royana Singh

Published in Reports (Volume 1, Issue 2)

Received: 20 February 2021 Accepted: 15 March 2021 Published: 9 July 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Endometriosis disease affects about an estimated number of 176 million women worldwide, which constitutes ~10% of the total female population causing debilitating symptoms of pelvic pain and infertility, thus limiting the quality of reproductive life of an affected woman. Progestins now have became a mainstay of endometriosis suppression, out of which dienogest has been opted as a best option worldwide. Its an expertise literature review with recommendations on the use of dienogest in the context of various clinical considerations when treating endometriosis disease. Experts have reviewed and included those, which they found to be considered most relevant in clinical practices, based on their own clinical experiences. Long-term uses (>15 months) of dienogest for the management of endometriosis is presented, with experts concluding that the efficacy of dienogest must be assessed primarily for its impact on pain and quality of life of a woman. Fertility preservation, avoiding or delaying surgery, and managing the bleeding irregularities occurring because of this medical treatment are also considered here. Counseling women on potential bleeding risks before starting the treatment may be helpful, as the evidences suggest that few of them discontinues the treatment because of this reason outweighing the benefits. Overall, the evidences demonstrate that dienogest offers an effective and tolerable alternative in adjunct to surgery and provids many advantages over combined hormonal contraceptives for the treatment of endometriosis. But its important for all that treatment guidelines must be followed strictly with great care and must be tailored to the woman’s individual needs and their desires.

Published in	Reports (Volume 1, Issue 2)
DOI	10.11648/j.reports.20210102.11
Page(s)	10-13
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Adolescents, Dysmenorrhea, Endometrioma, Endometriosis, Pelvic Pain

References

[1]	Acién, Pedro, and Irene Velasco. 2013. “Endometriosis: A Disease That Remains Enigmatic.” ISRN Obstetrics and Gynecology 2013: 1–12.
[2]	Adaji, Enemona, Anand Ahankari, and Puja Myles. 2017. “An Investigation to Identify Potential Risk Factors Associated with Common Chronic Diseases among the Older Population in India.” Indian Journal of Community Medicine 42 (1): 46–52.
[3]	Alio, L et al. 2019. “When More Is Not Better: 10 ‘Don’Ts’ in Endometriosis Management. An ETIC* Position Statement.” Human Reproduction Open 2019 (3).
[4]	de Almeida Asencio, Fernanda et al. 2019. “Symptomatic Endometriosis Developing Several Years after Menopause in the Absence of Increased Circulating Estrogen Concentrations: A Systematic Review and Seven Case Reports.” Gynecological Surgery 16 (1): 1–11.
[5]	As-Sanie, Sawsan et al. 2019. “Assessing Research Gaps and Unmet Needs in Endometriosis.” American Journal of Obstetrics and Gynecology 221 (2): 86–94.
[6]	Ashish, Ashish et al. 2021. 4 Acta Scientific Gastrointestinal Disorders The Role of Oxidative Stress and Antioxidant Effects in Female Endometriosis: A Systematic Review.
[7]	Ashish, Ashish, Kusum Kusum, Sangeeta Rai, and Royana Singh. 2020. “Endometriosis a Brief Review: Evaluation of Crucial Risk Factors and Current Treatment Regimes.” International Journal of Advances in Medicine 7 (12): 1896.
[8]	Audebert, Alain. 2018. “Endometriosis.” In Encyclopedia of Endocrine Diseases, MDText.com, Inc., 498–505.
[9]	Brosens, I., S. Gordts, and G. Benagiano. 2013. “Endometriosis in Adolescents Is a Hidden, Progressive and Severe Disease That Deserves Attention, Not Just Compassion.” Human Reproduction 28 (8): 2026–31.
[10]	Bulun, Serdar E. 2019. “Endometriosis.” In Yen & Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition, Elsevier Inc., 609-642. e7.
[11]	Carpinello, Olivia J et al. 2000. Endotext Endometriosis.
[12]	Donnez, Jacques. 2017. “Introduction: From Pathogenesis to Therapy, Deep Endometriosis Remains a Source of Controversy.” Fertility and Sterility 108 (6): 869–71.
[13]	Ebert, Andreas D. et al. 2017. “Dienogest 2 Mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents.” Journal of Pediatric and Adolescent Gynecology 30 (5): 560–67.
[14]	Eisenberg, V. H., C. Weil, G. Chodick, and V. Shalev. 2018. “Epidemiology of Endometriosis: A Large Population-Based Database Study from a Healthcare Provider with 2 Million Members.” BJOG: An International Journal of Obstetrics and Gynaecology 125 (1): 55–62.
[15]	Foti, Pietro Valerio et al. 2018. “Endometriosis: Clinical Features, MR Imaging Findings and Pathologic Correlation.” Insights into Imaging 9 (2): 149–72.
[16]	Giudice, Linda C, and Lee C Kao. 2004. “Endometriosis.” The Lancet 364 (9447): 1789–99.
[17]	Hsu, Albert L., Izabella Khachikyan, and Pamela Stratton. 2010. “Invasive and Noninvasive Methods for the Diagnosis of Endometriosis.” Clinical Obstetrics and Gynecology 53 (2): 413–19.
[18]	Klemmt, Petra AB, and Anna Starzinski-Powitz. 2017. “Molecular and Cellular Pathogenesis of Endometriosis.” Current Women s Health Reviews 13 (999): 1–11.
[19]	Kusum, Kusum et al. 2020. “Aromatase Gene Polymorphism (Rs2470152) in Polycystic Ovary Syndrome Patients of Eastern Uttar Pradesh Population.” Journal of Clinical and Diagnostic Research 14 (10): 3–7.
[20]	Kusum, Rai S, and Chaube R. 2019. “Endometriosis: Role of Aromatase and Recent Advances in the Disease Treatment.” Austin J Obstet Gynecol 6 (2).
[21]	Kyama, Cleophas M., Sophie Debrock, Jason M. Mwenda, and Thomas M. D’Hooghe. 2003. “Potential Involvement of the Immune System in the Development of Endometriosis.” Reproductive Biology and Endocrinology 1.
[22]	Miller, Jessica E. et al. 2017. “Interleukin-33 Modulates Inflammation in Endometriosis.” Scientific Reports 7 (1): 17903.
[23]	Moradi, Maryam et al. 2014. “Impact of Endometriosis on Women’s Lives: A Qualitative Study.” BMC Women’s Health 14 (1): 123.
[24]	Murji, Ally et al. 2020a. “Use of Dienogest in Endometriosis: A Narrative Literature Review and Expert Commentary.” Current Medical Research and Opinion 36 (5): 895–907.
[25]	P. V. Foti et al., “Endometriosis: clinical features, MR imaging findings and pathologic correlation,” Insights into Imaging, vol. 9, no. 2. pp. 149–172, 2018, doi: 10.1007/s13244-017-0591-0.
[26]	Riazi, Hedyeh et al. 2015. “Clinical Diagnosis of Pelvic Endometriosis: A Scoping Review.” BMC Women’s Health 15 (1): 01.
[27]	Rolla, Edgardo. 2019. “Endometriosis: Advances and Controversies in Classification, Pathogenesis, Diagnosis, and Treatment: [Version 1; Peer Review: 4 Approved].” F1000Research 8.
[28]	Saceanu, Sidonia Maria, Stefan Patrascu, Anca Patrascu, and Valeriu Surlin. 2017. “Endometriosis: When and How We Treat.” In Fertility-Oriented Female Reproductive Surgery,.
[29]	Shigesi, Nina et al. 2019. “The Association between Endometriosis and Autoimmune Diseases: A Systematic Review and Meta-Analysis.” Human Reproduction Update 25 (4): 486–503.
[30]	Zannoni, Letizia, Simona Del Forno, Roberto Paradisi, and Renato Seracchioli. 2016. “Endometriosis in Adolescence: Practical Rules for an Earlier Diagnosis.” Pediatric Annals 45 (9): e332–35.
[31]	Zondervan, Krina T. et al. 2018. “Endometriosis.” Nature Reviews Disease Primers 4 (1): 9.
[32]	S. Rai, Ashish, P. Kumari, A. Singh, and R. Singh, “Correlation of follicle-stimulating hormone receptor gene Asn 680 Ser (rs6166) polymorphism with female infertility,” J. Fam. Med. Prim. Care, vol. 8, no. 10, p. 3356, 2019.

Cite This Article

Plain Text BibTeX RIS

APA Style

Ashish Ashish, Kusum Kusum, Sangeeta Rai, Radha Chaube, Shivani Mishra, et al. (2021). Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes. Reports, 1(2), 10-13. https://doi.org/10.11648/j.reports.20210102.11

Copy | Download

ACS Style

Ashish Ashish; Kusum Kusum; Sangeeta Rai; Radha Chaube; Shivani Mishra, et al. Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes. Reports. 2021, 1(2), 10-13. doi: 10.11648/j.reports.20210102.11

Copy | Download

AMA Style

Ashish Ashish, Kusum Kusum, Sangeeta Rai, Radha Chaube, Shivani Mishra, et al. Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes. Reports. 2021;1(2):10-13. doi: 10.11648/j.reports.20210102.11

Copy | Download

@article{10.11648/j.reports.20210102.11,
  author = {Ashish Ashish and Kusum Kusum and Sangeeta Rai and Radha Chaube and Shivani Mishra and Royana Singh},
  title = {Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes},
  journal = {Reports},
  volume = {1},
  number = {2},
  pages = {10-13},
  doi = {10.11648/j.reports.20210102.11},
  url = {https://doi.org/10.11648/j.reports.20210102.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.reports.20210102.11},
  abstract = {Endometriosis disease affects about an estimated number of 176 million women worldwide, which constitutes ~10% of the total female population causing debilitating symptoms of pelvic pain and infertility, thus limiting the quality of reproductive life of an affected woman. Progestins now have became a mainstay of endometriosis suppression, out of which dienogest has been opted as a best option worldwide. Its an expertise literature review with recommendations on the use of dienogest in the context of various clinical considerations when treating endometriosis disease. Experts have reviewed and included those, which they found to be considered most relevant in clinical practices, based on their own clinical experiences. Long-term uses (>15 months) of dienogest for the management of endometriosis is presented, with experts concluding that the efficacy of dienogest must be assessed primarily for its impact on pain and quality of life of a woman. Fertility preservation, avoiding or delaying surgery, and managing the bleeding irregularities occurring because of this medical treatment are also considered here. Counseling women on potential bleeding risks before starting the treatment may be helpful, as the evidences suggest that few of them discontinues the treatment because of this reason outweighing the benefits. Overall, the evidences demonstrate that dienogest offers an effective and tolerable alternative in adjunct to surgery and provids many advantages over combined hormonal contraceptives for the treatment of endometriosis. But its important for all that treatment guidelines must be followed strictly with great care and must be tailored to the woman’s individual needs and their desires.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes
AU  - Ashish Ashish
AU  - Kusum Kusum
AU  - Sangeeta Rai
AU  - Radha Chaube
AU  - Shivani Mishra
AU  - Royana Singh
Y1  - 2021/07/09
PY  - 2021
N1  - https://doi.org/10.11648/j.reports.20210102.11
DO  - 10.11648/j.reports.20210102.11
T2  - Reports
JF  - Reports
JO  - Reports
SP  - 10
EP  - 13
PB  - Science Publishing Group
SN  - 2994-7146
UR  - https://doi.org/10.11648/j.reports.20210102.11
AB  - Endometriosis disease affects about an estimated number of 176 million women worldwide, which constitutes ~10% of the total female population causing debilitating symptoms of pelvic pain and infertility, thus limiting the quality of reproductive life of an affected woman. Progestins now have became a mainstay of endometriosis suppression, out of which dienogest has been opted as a best option worldwide. Its an expertise literature review with recommendations on the use of dienogest in the context of various clinical considerations when treating endometriosis disease. Experts have reviewed and included those, which they found to be considered most relevant in clinical practices, based on their own clinical experiences. Long-term uses (>15 months) of dienogest for the management of endometriosis is presented, with experts concluding that the efficacy of dienogest must be assessed primarily for its impact on pain and quality of life of a woman. Fertility preservation, avoiding or delaying surgery, and managing the bleeding irregularities occurring because of this medical treatment are also considered here. Counseling women on potential bleeding risks before starting the treatment may be helpful, as the evidences suggest that few of them discontinues the treatment because of this reason outweighing the benefits. Overall, the evidences demonstrate that dienogest offers an effective and tolerable alternative in adjunct to surgery and provids many advantages over combined hormonal contraceptives for the treatment of endometriosis. But its important for all that treatment guidelines must be followed strictly with great care and must be tailored to the woman’s individual needs and their desires.
VL  - 1
IS  - 2
ER  -

Copy | Download

Author Information

Ashish Ashish

Department of Anatomy, Institute of Medical Science, Banaras Hindu University, Varanasi, India
Kusum Kusum

Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India
Sangeeta Rai

Department of Obstetrics & Gynaecology, Institute of Medical Science, Banaras Hindu University, Varanasi, India
Radha Chaube

Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India
Shivani Mishra

Department of Anatomy, Institute of Medical Science, Banaras Hindu University, Varanasi, India
Royana Singh

Department of Anatomy, Institute of Medical Science, Banaras Hindu University, Varanasi, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Ashish Ashish, Kusum Kusum, Sangeeta Rai, Radha Chaube, Shivani Mishra, et al. (2021). Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes. Reports, 1(2), 10-13. https://doi.org/10.11648/j.reports.20210102.11

Copy | Download

ACS Style

Ashish Ashish; Kusum Kusum; Sangeeta Rai; Radha Chaube; Shivani Mishra, et al. Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes. Reports. 2021, 1(2), 10-13. doi: 10.11648/j.reports.20210102.11

Copy | Download

AMA Style

Ashish Ashish, Kusum Kusum, Sangeeta Rai, Radha Chaube, Shivani Mishra, et al. Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes. Reports. 2021;1(2):10-13. doi: 10.11648/j.reports.20210102.11

Copy | Download

@article{10.11648/j.reports.20210102.11,
  author = {Ashish Ashish and Kusum Kusum and Sangeeta Rai and Radha Chaube and Shivani Mishra and Royana Singh},
  title = {Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes},
  journal = {Reports},
  volume = {1},
  number = {2},
  pages = {10-13},
  doi = {10.11648/j.reports.20210102.11},
  url = {https://doi.org/10.11648/j.reports.20210102.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.reports.20210102.11},
  abstract = {Endometriosis disease affects about an estimated number of 176 million women worldwide, which constitutes ~10% of the total female population causing debilitating symptoms of pelvic pain and infertility, thus limiting the quality of reproductive life of an affected woman. Progestins now have became a mainstay of endometriosis suppression, out of which dienogest has been opted as a best option worldwide. Its an expertise literature review with recommendations on the use of dienogest in the context of various clinical considerations when treating endometriosis disease. Experts have reviewed and included those, which they found to be considered most relevant in clinical practices, based on their own clinical experiences. Long-term uses (>15 months) of dienogest for the management of endometriosis is presented, with experts concluding that the efficacy of dienogest must be assessed primarily for its impact on pain and quality of life of a woman. Fertility preservation, avoiding or delaying surgery, and managing the bleeding irregularities occurring because of this medical treatment are also considered here. Counseling women on potential bleeding risks before starting the treatment may be helpful, as the evidences suggest that few of them discontinues the treatment because of this reason outweighing the benefits. Overall, the evidences demonstrate that dienogest offers an effective and tolerable alternative in adjunct to surgery and provids many advantages over combined hormonal contraceptives for the treatment of endometriosis. But its important for all that treatment guidelines must be followed strictly with great care and must be tailored to the woman’s individual needs and their desires.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes
AU  - Ashish Ashish
AU  - Kusum Kusum
AU  - Sangeeta Rai
AU  - Radha Chaube
AU  - Shivani Mishra
AU  - Royana Singh
Y1  - 2021/07/09
PY  - 2021
N1  - https://doi.org/10.11648/j.reports.20210102.11
DO  - 10.11648/j.reports.20210102.11
T2  - Reports
JF  - Reports
JO  - Reports
SP  - 10
EP  - 13
PB  - Science Publishing Group
SN  - 2994-7146
UR  - https://doi.org/10.11648/j.reports.20210102.11
AB  - Endometriosis disease affects about an estimated number of 176 million women worldwide, which constitutes ~10% of the total female population causing debilitating symptoms of pelvic pain and infertility, thus limiting the quality of reproductive life of an affected woman. Progestins now have became a mainstay of endometriosis suppression, out of which dienogest has been opted as a best option worldwide. Its an expertise literature review with recommendations on the use of dienogest in the context of various clinical considerations when treating endometriosis disease. Experts have reviewed and included those, which they found to be considered most relevant in clinical practices, based on their own clinical experiences. Long-term uses (>15 months) of dienogest for the management of endometriosis is presented, with experts concluding that the efficacy of dienogest must be assessed primarily for its impact on pain and quality of life of a woman. Fertility preservation, avoiding or delaying surgery, and managing the bleeding irregularities occurring because of this medical treatment are also considered here. Counseling women on potential bleeding risks before starting the treatment may be helpful, as the evidences suggest that few of them discontinues the treatment because of this reason outweighing the benefits. Overall, the evidences demonstrate that dienogest offers an effective and tolerable alternative in adjunct to surgery and provids many advantages over combined hormonal contraceptives for the treatment of endometriosis. But its important for all that treatment guidelines must be followed strictly with great care and must be tailored to the woman’s individual needs and their desires.
VL  - 1
IS  - 2
ER  -

Copy | Download